SymbolANABV
NameANAPTYSBIO, INC
SectorHEALTH CARE
RegionUNDEFINED
IndustryPharmaceutical Preparations
Address10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA 92121
Telephone858-362-6295
Fax
Email
Websitehttps://www.anaptysbio.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

Additional info from NASDAQ:
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

2026-04-24 19:40

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

Read more
2026-04-24 17:17

New Form 8-K/A - ANAPTYSBIO, INC <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177317 <b>Size:</b> 303 KB <br />Item 9.01: Financial Statements and Exhibits

Read more
2026-04-23 19:08

New Form 4/A - ANAPTYSBIO, INC <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001673528-26-000012 <b>Size:</b> 5 KB

Read more
2026-04-22 22:35

Schmid John P. 🟡 adjusted position in 0 shares (20 derivative) of ANAPTYSBIO, INC (ANAB) at $104.81 ($5.7M) Transaction Date: Apr 20, 2026 | Filing ID: 000006

Read more
2026-04-22 22:34

RENTON HOLLINGS 🟡 adjusted position in 0 shares (20 derivative) of ANAPTYSBIO, INC (ANAB) at $104.81 ($5.7M) Transaction Date: Apr 20, 2026 | Filing ID: 000002

Read more
2026-04-22 22:33

Faga Daniel 🟡 adjusted position in 5.5K shares (14 derivative) of ANAPTYSBIO, INC (ANAB) at $43.91 ($41.2M) Transaction Date: Apr 20, 2026 | Filing ID: 000011

Read more
2026-04-20 21:25

(99% Neutral) ANAPTYSBIO, INC (ANABV) Announces Business Combination

Read more
2026-04-20 13:15

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Read more
2026-04-06 13:35

AnaptysBio, Inc. - Common Stock When Issued (ANABV) was added to the exchange traded list on NASDAQ

Read more
2026-04-03 17:01

New Form 3 - ANAPTYSBIO, INC <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001833453-26-000002 <b>Size:</b> 8 KB

Read more